UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

Date of Report (Date of earliest event reported):  October 27, 2015

AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)

 
 
 
Delaware
 
 
000-50761
 
 
11-3146460
 
(State or Other Jurisdiction of Incorporation)
 
 
(Commission File
Number)
(IRS Employer
Identification No.)
 
  
 
 
14 Plaza Drive, Latham, New York      12110
  
 
 
(Address of Principal Executive Offices)                 (Zip Code)
 
 
  
   
 
 
(518) 798-1215
  
 
 
(Registrant’s telephone number, including area code)
 
  
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
 
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 

 
Item 5.07 – Submission of Matters to a Vote of Security Holders.

(a)
AngioDynamics’ Annual Meeting of Shareholders was held on October 27, 2015.

(b)
Shareholders voted on the matters set forth below.

1.
The nominees for election to the Board of Directors were elected, each as a Class III director to serve until the 2018 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:

 
Nominee
  
Votes For
  
Withheld
  
Broker Non Votes
 
 
 
David Burgstahler
  
 
 
28,860,112
  
 
 
1,425,622
  
 
 
2,161,600
 
 
 
Wesley E. Johnson, Jr.
  
 
 
28,919,069
  
 
 
1,366,665
  
 
 
2,161,600
 
 
 
Steven R. LaPorte
  
 
 
28,529,540
  
 
 
1,756,194
  
 
 
2,161,600
 

 
2.
The proposal to ratify the appointment of PricewaterhouseCoopers LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2016 was approved based upon the following votes:

 
Votes for approval
31,541,627
 
Votes against
899,321
 
Abstentions
6,386
 
There were no broker non-votes for this item.
  


3.
The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers was approved based upon the following votes:

 
Votes for approval
26,997,085
 
Votes against
3,278,322
 
Abstentions
10,327
 
Broker non votes
2,161,600


(c)
Not applicable.

(d)
Not applicable.





SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
ANGIODYNAMICS, INC.
(Registrant)
  
       
Date: November 2, 2015
By:
/s/ Stephen A. Trowbridge  
    Stephen A. Trowbridge  
    Senior Vice President and General Counsel